Hanno Glimm

Dresden, SN, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 150 publications

17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing?

17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing?

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Glucocorticoids induce a phagocytic C1Q+ macrophage phenotype primed for IFNγ-dependent CXCL9 secretion.

Glucocorticoids induce a phagocytic C1Q+ macrophage phenotype primed for IFNγ-dependent CXCL9 secretion.

Journal: Scientific reports

Published: November 12, 2025

Targeted therapy in patients with genetic tumor syndromes.

Targeted therapy in patients with genetic tumor syndromes.

Journal: Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V

Published: November 10, 2025

Integration and validation of complementary ex vivo assays for functional precision oncology.

Integration and validation of complementary ex vivo assays for functional precision oncology.

Journal: NPJ precision oncology

Published: October 30, 2025

Deep molecular profiling of biliary tract cancer uncovers novel biological mechanisms and therapeutic opportunities.

Deep molecular profiling of biliary tract cancer uncovers novel biological mechanisms and therapeutic opportunities.

Journal: ESMO open

Published: September 16, 2025

Cell cycle regulator MYBL2 is a distinct vulnerability in acute myeloid leukemia.

Cell cycle regulator MYBL2 is a distinct vulnerability in acute myeloid leukemia.

Journal: Cell death discovery

Published: July 30, 2025

Rationale and design of the PAMSARC (pasireotide as maintenance treatment with monthly deep intramuscular injection in SSTR2/3/5-expressing synovial sarcoma and desmoplastic small round cell tumor) multicenter phase 2 trial.

Rationale and design of the PAMSARC (pasireotide as maintenance treatment with monthly deep intramuscular injection in SSTR2/3/5-expressing synovial sarcoma and desmoplastic small round cell tumor) multicenter phase 2 trial.

Journal: Cancer treatment and research communications

Published: July 29, 2025

Clinically actionable genomic and transcriptomic landscape of advanced neuroendocrine neoplasms.

Clinically actionable genomic and transcriptomic landscape of advanced neuroendocrine neoplasms.

Journal: Med (New York, N.Y.)

Published: July 27, 2025

Mismatch repair deficiency and microsatellite instability in adrenocortical carcinoma.

Mismatch repair deficiency and microsatellite instability in adrenocortical carcinoma.

Journal: ESMO open

Published: July 22, 2025

Advancing sarcoma diagnostics with expanded DNA methylation-based classification.

Advancing sarcoma diagnostics with expanded DNA methylation-based classification.

Journal: medRxiv : the preprint server for health sciences

Published: July 09, 2025

Pansarcoma Analysis of Cyclin-Dependent Kinase and Cyclin Outlier Gene Expression Highlights CDK7 as a Potential Therapeutic Target in Chordoma.

Pansarcoma Analysis of Cyclin-Dependent Kinase and Cyclin Outlier Gene Expression Highlights CDK7 as a Potential Therapeutic Target in Chordoma.

Journal: JCO precision oncology

Published: July 02, 2025

Last Resort? Rationale for Comprehensive Molecular Analysis in Treatment-Refractory R/M HNSCC: A Case Report of Remarkable Response to Sacituzumab Govitecan Following Molecular and Functional Characterization.

Last Resort? Rationale for Comprehensive Molecular Analysis in Treatment-Refractory R/M HNSCC: A Case Report of Remarkable Response to Sacituzumab Govitecan Following Molecular and Functional Characterization.

Journal: Biomedicines

Published: April 02, 2025

Showing 1-12 of 150

Last Updated: 09/26/2026